Alvesco (Ciclesonide Inhaled)
ciclesonide inhalation aerosol
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Persistent asthma — maintenance prophylaxis | ≥12 years | Monotherapy or adjunctive | FDA Approved |
Ciclesonide inhaled (Alvesco) is approved for the maintenance treatment of asthma as prophylactic therapy in patients 12 years of age and older. Notably, ciclesonide is not approved for children under 12 — clinical trials in patients 2–11 years of age failed to demonstrate efficacy, and the drug is not indicated for this population. Ciclesonide is not for the relief of acute bronchospasm. As a prodrug that is activated locally in the lungs, ciclesonide is designed to minimize oropharyngeal side effects while maintaining airway anti-inflammatory activity. GINA and NAEPP guidelines position it as a step 2–4 controller option.
Exercise-induced bronchoconstriction (EIB) prophylaxis: Regular daily ciclesonide use as controller therapy has been studied for reducing the severity and frequency of EIB episodes. The efficacy for this specific use has been examined in clinical trials in adults. Evidence quality: Moderate.
Eosinophilic bronchitis without asthma: ICS therapy is recommended by ACCP guidelines for chronic cough with sputum eosinophilia; ciclesonide may be used. Evidence quality: Low (extrapolated from ICS class).
Dosing
Adults & Adolescents (≥12 Years)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Mild persistent asthma — previously on bronchodilators only | 80 mcg twice daily | 80 mcg BID | 160 mcg BID (320 mcg/day) | Titrate to lowest effective dose once stable Onset of full benefit: up to 4 weeks or longer |
| Moderate persistent asthma — previously on inhaled corticosteroids | 80 mcg twice daily | 80–320 mcg BID | 320 mcg BID (640 mcg/day) | Increase after 4 weeks if inadequate response Higher ceiling than bronchodilator-only group |
| Severe asthma — transitioning from oral corticosteroids | 320 mcg twice daily | 320 mcg BID | 320 mcg BID (640 mcg/day) | Reduce prednisone by 2.5 mg/day on a weekly basis after ≥1 week of ciclesonide Monitor for adrenal insufficiency during taper |
Ciclesonide is inactive until cleaved by esterases in the lung to its active metabolite, des-ciclesonide. This prodrug design means that steroid deposited in the oropharynx remains largely inactive, which is a key reason that oral candidiasis rates with ciclesonide are among the lowest of all ICS agents (<1% in clinical trials vs 4–6% with many other ICS). This makes ciclesonide particularly attractive for patients who have experienced recurrent thrush with other inhaled steroids. Twice-daily dosing is the optimum regimen; clinical trials showed that BID administration produces significantly greater FEV1 improvement than the same total daily dose given once daily (FDA PI).
Pharmacology
Mechanism of Action
Ciclesonide is a non-halogenated glucocorticoid prodrug that is itself pharmacologically inactive. After inhalation, airway esterases hydrolyze ciclesonide to its active metabolite, des-ciclesonide (C21-desisobutyryl-ciclesonide). Des-ciclesonide binds to intracellular glucocorticoid receptors with an affinity 120 times greater than the parent compound and 12 times greater than dexamethasone. The activated receptor complex translocates to the nucleus and modulates gene transcription, suppressing multiple inflammatory cell types (eosinophils, mast cells, macrophages, lymphocytes) and mediators (cytokines, leukotrienes, histamine). Because activation occurs predominantly in the lower airways rather than the oropharynx, ciclesonide achieves a favorable ratio of local anti-inflammatory effect to oropharyngeal side effects compared to directly active ICS agents.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Oral bioavailability <1% (both ciclesonide and des-ciclesonide); absolute bioavailability via inhalation: 22% (ciclesonide), 63% relative (des-ciclesonide); Tmax des-ciclesonide: 1.04 h | Negligible oral absorption ensures that the swallowed fraction contributes almost nothing to systemic exposure; all clinically relevant absorption is pulmonary |
| Distribution | Vd ciclesonide: 2.9 L/kg; Vd des-ciclesonide: 12.1 L/kg; protein binding ≥99% for both; des-ciclesonide is not bound to transcortin | Extensive tissue distribution of the active metabolite supports prolonged local effect; very high protein binding limits free systemic drug |
| Metabolism | Prodrug hydrolysis by lung esterases to des-ciclesonide; further hepatic metabolism via CYP3A4 (major) and CYP2D6 (minor); no significant CYP inhibition or induction | Lung-selective activation is the pharmacological basis for reduced oropharyngeal side effects; CYP3A4 inhibitors can increase des-ciclesonide exposure (ketoconazole ↑3.6-fold) |
| Elimination | t½ ciclesonide: 0.71 h; t½ des-ciclesonide: 6–7 h; clearance: 152 L/hr (ciclesonide), 228 L/hr (des-ciclesonide); 66% fecal, ≤20% urinary | Rapid clearance of parent compound; the 6–7 h half-life of the active metabolite supports twice-daily dosing; predominantly biliary excretion means no dose adjustment in renal impairment |
Side Effects
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nasopharyngitis | 7.0–10.5% | Most common reaction across all dose groups; rates similar to or slightly higher than placebo (7.5%) |
| Headache | 4.9–11.0% | Highest at 160 mcg BID (11.0%); placebo rate was 7.3%; generally mild and self-limiting |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Upper respiratory tract infection | 4.1–8.7% | Similar to other ICS agents; not clearly dose-related |
| Sinusitis | 3.1–5.5% | Slightly above placebo (3.0%); may reflect background atopic disease |
| Pharyngolaryngeal pain | 2.4–4.7% | Similar to placebo rate (4.3%); lower than many other ICS due to prodrug design |
| Nasal congestion | 1.8–5.5% | More frequent at 160 mcg BID (5.5%) vs placebo (1.6%) |
| Arthralgia | 0.9–3.5% | Dose-related; highest at 320 mcg BID (3.5%) vs placebo (1.0%) |
| Pain in extremity | 0.3–3.1% | More common at 160 mcg BID; clinical significance uncertain |
| Back pain | 0.6–3.1% | Rates comparable to placebo (2.0%) at most doses |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Adrenal suppression / HPA axis dysfunction | Rare at recommended doses | Weeks to months (high doses or concurrent CYP3A4 inhibitors) | Gradual dose reduction; AM cortisol or ACTH stimulation test; systemic steroid supplementation during physiological stress |
| Angioedema / hypersensitivity (lips, tongue, pharynx) | Rare (postmarketing) | Minutes to hours | Immediate emergency treatment; permanent discontinuation of ciclesonide |
| Paradoxical bronchospasm | Rare | Immediately after inhalation | Treat with rescue bronchodilator; discontinue ciclesonide; switch to alternative ICS |
| Posterior subcapsular cataracts | 0.9% (1-year comparator trial: 743 patients on ciclesonide 320 mcg BID) | Months to years | Periodic ophthalmological examination; refer for any change in vision |
| Glaucoma / raised intraocular pressure | Reported (ICS class effect); CLASS III lens changes 8.1% in 1-year trial | Months to years | Regular IOP monitoring in patients with risk factors; ophthalmology referral for visual symptoms |
| Reduced bone mineral density | ICS class effect; long-term significance unknown | Years of continuous use | DEXA scan in patients with osteoporosis risk factors; calcium and vitamin D supplementation |
| Growth suppression (pediatric — ICS class) | ~1 cm/year reduction (range 0.3–1.8 cm/year); inconclusive for ciclesonide specifically | First year of treatment | Routine stadiometry; titrate to lowest effective dose; 52-week ciclesonide growth study was inconclusive due to compliance issues |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Asthma worsening | Lower than placebo | Fewer patients on ciclesonide experienced worsening compared to placebo in all trials |
| Oral candidiasis | <1% | 32 of 3038 patients total (1.05%); only 20 at ≥320 mcg/day; rarely led to discontinuation |
Oral candidiasis occurred in only 32 of 3038 patients (approximately 1.05%) across the ciclesonide clinical program — a rate that is substantially lower than most other ICS agents (typically 4–6%). This is attributable to the prodrug mechanism: ciclesonide remains inactive in the oropharynx and is only converted to the active metabolite des-ciclesonide by esterases concentrated in the lower airways. This advantage makes ciclesonide an appealing option for patients with a history of recurrent ICS-related thrush.
Drug Interactions
Des-ciclesonide is metabolized primarily by CYP3A4 after lung activation. In vitro, des-ciclesonide has no significant potential to inhibit or induce major CYP enzymes, and its protein binding is unaffected by warfarin or salicylates. Clinical studies confirmed no pharmacokinetic interactions between ciclesonide and albuterol or formoterol. The primary interaction concern is with potent CYP3A4 inhibitors that increase des-ciclesonide systemic exposure.
Monitoring
-
Lung Function (FEV1 / PEF)
Baseline; 4 weeks after initiation; then every 3–12 months
Routine Spirometry confirms treatment response. Full benefit may take 4 weeks or longer. If inadequate after 4 weeks, consider dose increase before switching agents. -
Oropharyngeal Examination
Each visit
Routine Although candidiasis rates are very low with ciclesonide (<1%), routine inspection remains standard ICS practice. Reinforce mouth rinsing after each dose. -
Growth Velocity (Pediatric)
Every 3–6 months via stadiometry
Routine ICS class effect applies. The dedicated ciclesonide growth study (609 patients aged 5–8.5 years) was inconclusive due to compliance issues. Monitor growth as with any ICS. -
Ophthalmological Assessment
Annually for long-term users; sooner if symptoms
Routine In a 1-year comparator trial, posterior subcapsular opacities occurred in 0.9% of ciclesonide-treated patients vs 0.5% with comparator ICS. Screen for cataracts and glaucoma. -
Bone Mineral Density
Baseline if risk factors; then per clinical judgment
Trigger-based DEXA scan in patients with osteoporosis risk factors. Supplement with calcium and vitamin D as appropriate. -
Adrenal Function
During steroid transition; if Cushingoid features develop
Trigger-based Morning cortisol or ACTH stimulation test during oral steroid taper or when using high-dose ciclesonide with concurrent CYP3A4 inhibitors. In a 29-day HPA study, ciclesonide at 640 and 1280 mcg/day did not significantly affect 24-hr urinary cortisol vs placebo. -
Inhaler Technique
Every visit
Routine Verify correct MDI technique (slow deep inhalation). Confirm priming: 3 actuations before first use or after >10 days unused. Discard when dose counter shows zero.
Contraindications & Cautions
Absolute Contraindications
- Status asthmaticus or acute bronchospasm requiring intensive measures — ciclesonide is a controller, not a reliever; it has no role in acute asthma emergencies.
- Known hypersensitivity to ciclesonide or any excipient — rare postmarketing cases of angioedema involving the lips, tongue, and pharynx have been reported.
Relative Contraindications (Specialist Input Recommended)
- Active pulmonary tuberculosis — ICS may worsen untreated TB. Screen before initiating long-term therapy in high-risk populations.
- Active untreated systemic fungal, bacterial, viral, or parasitic infections — use with caution, if at all.
- Ocular herpes simplex — corticosteroids may promote corneal perforation.
- Recent transfer from high-dose systemic corticosteroids — risk of ongoing adrenal insufficiency; joint management with endocrinology may be needed for complex tapers.
Use with Caution
- Hepatic impairment — des-ciclesonide exposure increases 1.4–2.7-fold in moderate-to-severe hepatic impairment, although dose adjustment is not required per the PI.
- Concurrent potent CYP3A4 inhibitors — ketoconazole increases des-ciclesonide AUC 3.6-fold; monitor for systemic corticosteroid effects.
- Osteoporosis risk factors — prolonged ICS use can contribute to BMD loss.
- Patients with glaucoma or cataracts — close monitoring warranted with long-term use.
- Immunocompromised patients — chickenpox and measles can be more serious; ensure immunity before starting.
Deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to inhaled corticosteroids. Patients previously maintained on 20 mg/day or more of prednisone (or equivalent) may be particularly susceptible. Taper systemic steroids gradually (reduce prednisone by no more than 2.5 mg/day on a weekly basis) after at least 1 week of ciclesonide therapy. Patients should carry a medical identification card indicating need for supplementary systemic steroids during physiological stress.
Patient Counselling
Purpose of Therapy
Ciclesonide (Alvesco) is a daily controller medication that works by reducing airway inflammation over time to prevent asthma symptoms and attacks. It is a special type of steroid that is only activated once it reaches the lungs, which helps reduce side effects in the mouth and throat compared to other inhaled steroids. It does not provide instant relief during an asthma attack.
How to Take
Use ciclesonide at the same times each day, twice daily, whether or not symptoms are present. Prime the inhaler with 3 sprays before the first use or if unused for more than 10 days. After each dose, rinse the mouth with water and spit it out. Full benefit may take 4 weeks or longer to develop. Discard the inhaler when the dose counter reaches zero. Always have a separate rescue inhaler (such as albuterol) available.
Sources
- Alvesco (ciclesonide) inhalation aerosol prescribing information. Covis Pharma. Revised 02/2023. FDA Label Primary source for all dosing, adverse reaction rates (Table 2), pharmacokinetic parameters, contraindications, and interaction data.
- DailyMed — Alvesco (ciclesonide) label. National Library of Medicine. DailyMed Mirror of current FDA-approved labeling with structured drug data.
- Boulet LP, Bateman ED, Voves R, et al. A randomized study comparing ciclesonide and fluticasone propionate in patients with moderate persistent asthma. Respir Med. 2007;101(8):1677–1686. DOI Head-to-head trial demonstrating comparable efficacy of ciclesonide 320 mcg/day to fluticasone 440 mcg/day with a favorable oropharyngeal side-effect profile.
- Postma DS, Bentley A, Engel M, et al. Inhaled ciclesonide versus fluticasone in moderate-to-severe asthma: effects on oropharyngeal adverse events. Eur Respir J. 2006;28(Suppl 50):524s. Supporting data for the prodrug advantage of ciclesonide with respect to oropharyngeal candidiasis and dysphonia rates.
- Chapman KR, Patel P, D’Urzo AD, et al. Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. Allergy. 2005;60(3):330–337. DOI Trial of once-daily ciclesonide; contributed to the understanding that twice-daily dosing is the optimum regimen.
- Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2024 Update. GINA Reports International guideline positioning ICS as step 2–5 controller therapy for persistent asthma.
- National Asthma Education and Prevention Program (NAEPP). Expert Panel Report 4: Guidelines for the Diagnosis and Management of Asthma. 2020. NHLBI US guideline providing step-care classification; classifies ciclesonide 160–320 mcg/day as low-dose and 320–640 mcg/day as medium-dose ICS.
- Nave R, Mueller H. From prodrug to active metabolite: the development rationale for ciclesonide. Curr Med Res Opin. 2006;22(9):1671–1684. DOI Comprehensive review of the prodrug design rationale, lung esterase activation, and the pharmacological basis for reduced oropharyngeal deposition effects.
- Rohatagi S, Luo Y, Shen L, et al. Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide. Am J Ther. 2005;12(3):201–209. DOI Demonstrates the ≥99% protein binding of des-ciclesonide and its contribution to the favorable systemic safety profile.
- Nave R, Bethke TD, van Marle SP, Zech K. Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects. Clin Pharmacokinet. 2004;43(7):479–486. DOI Key PK study establishing ciclesonide’s absolute bioavailability (22% inhaled), half-life, volume of distribution, and fecal elimination (66%).
- Derendorf H, Nave R, Drollmann A, et al. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J. 2006;28(5):1042–1050. DOI Review of ICS PK/PD principles placing ciclesonide in context with other agents regarding receptor affinity, protein binding, and systemic exposure.
- Nave R, Zech K, Bethke TD. Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects. Eur J Clin Pharmacol. 2005;61(3):203–208. DOI Demonstrates that ciclesonide HFA MDI achieves lower oropharyngeal drug deposition than budesonide CFC MDI, supporting the reduced candidiasis advantage.